超越糖化血红蛋白的1型糖尿病临床有意义结局指标的标准化:美国临床内分泌医师协会、美国糖尿病教育者协会、美国糖尿病协会、内分泌学会、JDRF国际、Leona M.和Harry B. Helmsley慈善信托、儿科内分泌学会及T1D Exchange的共识报告
该共识报告由多个专业组织组成的指导委员会制定,旨在识别和定义1型糖尿病超越糖化血红蛋白的临床有意义结局,优先结局包括低血糖、高血糖、范围内时间、糖尿病酮症酸中毒和患者报告结局。指导委员会为这些结局制定了定义,并建议在1型糖尿病疗法的研究、开发和评估中使用这些定义。
要点
- 优先结局包括低血糖、高血糖、范围内时间、糖尿病酮症酸中毒和患者报告结局。
- 指导委员会为低血糖、高血糖、范围内时间和糖尿病酮症酸中毒制定了定义。
- 指导委员会建议在1型糖尿病疗法的研究、开发和评估中使用这些定义的结局。
核心结论
- 指导委员会建议在1型糖尿病疗法的研究、开发和评估中使用所定义的超越糖化血红蛋白的临床有意义结局。
研究设计与样本
- 指导委员会由美国临床内分泌医师协会、美国糖尿病教育者协会、美国糖尿病协会、内分泌学会、JDRF国际、Leona M.和Harry B. Helmsley慈善信托、儿科内分泌学会及T1D Exchange的代表组成,是1型糖尿病结局项目的决策机构。
- 指导委员会的工作参考了来自研究者、行业和糖尿病患者的咨询委员会的意见,并通过利益相关者调查确定优先结局。
主要发现
- 调查中优先确定的结局为低血糖、高血糖、范围内时间、糖尿病酮症酸中毒和患者报告结局。
- 指导委员会为1型糖尿病的低血糖、高血糖、范围内时间和糖尿病酮症酸中毒制定了定义。
- 指导委员会讨论了患者报告结局,并得出结论认为需要进一步开发1型糖尿病特异性的患者报告结局。
- 识别了未来研究需要解决的知识空白。
关键数值与推荐
- 指导委员会建议在1型糖尿病疗法的研究、开发和评估中使用所定义的超越糖化血红蛋白的临床有意义结局。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To identify and define clinically meaningful type 1 diabetes outcomes beyond hemoglobin A1c (HbA1c) based upon a review of the evidence, consensus from clinical experts, and input from researchers, people with type 1 diabetes, and industry. Priority outcomes include hypoglycemia, hyperglycemia, time in range, diabetic ketoacidosis (DKA), and patient-reported outcomes (PROs). While priority outcomes for type 1 and type 2 diabetes may overlap, type 1 diabetes was the focus of this work. RESEARCH AND METHODS: A Steering Committee-comprising representatives from the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange-was the decision-making body for the Type 1 Diabetes Outcomes Program. Their work was informed by input from researchers, industry, and people with diabetes through Advisory Committees representing each stakeholder group. Stakeholder surveys were used to identify priority outcomes. The outcomes prioritized in the surveys were hypoglycemia, hyperglycemia, time in range, DKA, and PROs. To develop consensus on the definitions of these outcomes, the Steering Committee relied on published evidence, their clinical expertise, and feedback from the Advisory Committees. RESULTS: The Steering Committee developed definitions for hypoglycemia, hyperglycemia, time in range, and DKA in type 1 diabetes. The definitions reflect their assessment of the outcome's short- and long-term clinical impact on people with type 1 diabetes. Knowledge gaps to be addressed by future research were identified. The Steering Committee discussed PROs and concluded that further type 1 diabetes-specific development is needed. CONCLUSIONS: The Steering Committee recommends use of the defined clinically meaningful outcomes beyond HbA1c in the research, development, and evaluation of type 1 diabetes therapies.
引用
- Agiostratidou G, Anhalt H, Ball D, et al. Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange. Diabetes Care. 2017. PMID: 29162582. doi:10.2337/dc17-1624
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。